- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT05007483
Eficácia da Dieta na Qualidade de Vida na Esclerose Múltipla (EDQ)
The overarching goal of this project is to critically evaluate the efficacy of incorporating dietary guidance within multiple sclerosis (MS) care for improving long-term quality of life (QoL) compared to usual care. The primary objective of this study is to evaluate the effect of two dietary interventions (time restricted olive oil based (TROO) ketogenic and modified Paleolithic elimination) on MS QoL compared to usual care control (Dietary Guidelines for America), and the secondary objectives and the long-term effects on, motor function, low-contrast vision sensitivity, fatigue, mood, and disease activity assessed by brain imaging.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
- Suplemento dietético: BodyBio Balance Oil
- Suplemento dietético: Kirunal Fish Oil
- Suplemento dietético: BodyBio PC
- Comportamental: Modified Paleolithic Elimination diet
- Comportamental: Time Restricted Olive Oil Based (TROO) Ketogenic Diet
- Comportamental: Usual diet with Dietary Guidelines for Americans Diet information
Descrição detalhada
In the United States, MS affects nearly 1 million people with a 2.8:1 female to male ratio and the highest incidence rates among whites and African Americans. The economic cost of managing MS is substantial. In the U.S., the total medical costs for patients with MS increased from $116 million in 2002 to $198 million in 2013. MS is a chronic, neuroinflammatory, and neurodegenerative disease-causing symptoms of pain, fatigue, and changes in vision, cognition, and movement that greatly reduce quality of life (QoL) and the ability to maintain employment.
The overarching goal of this project is to critically evaluate the efficacy of incorporating dietary guidance within multiple sclerosis (MS) care for improving long-term quality of life (QoL) compared to usual care. The primary objective of this study is to evaluate the effect of two dietary interventions (time restricted olive oil based (TROO) ketogenic and modified Paleolithic elimination) on MS QoL compared to usual care control (Dietary Guidelines for America), and the secondary objectives and the long-term effects on, motor function, low-contrast vision sensitivity, fatigue, mood, and disease activity assessed by brain imaging.
The proposed study will consist of study participants attending 3 in-person site visits, months 0, 3, and 24, and online surveys every 3 months (months 0-24).
This study will use a randomized single-blind controlled design to test the short-term (6 months) and long-term (an additional 18 months) impact of the intervention diets on symptoms of MS including QoL and related outcomes stated above. We will use a fourteen-day run-in period to identify participants who are most likely to be successful in completing study procedures; this process has been effective in our previous studies. Participants who successfully complete all baseline self-reported outcomes and follow all study procedures during the seven-day run-in period will be scheduled for an on-site baseline visit for randomization to one of three diets (time restricted olive oil based (TROO) ketogenic and modified Paleolithic elimination and Dietary Guidelines for America).
On-site study visits will include blood draws, motor, cognitive, vision function assessments, and MRI. Motor assessments will include a 6-minute walk test, 25-foot walk test, 9-hole pegboard to test hand function, symbol digit exercise to test thinking functions, and critical flicker fusion test, ocular coherence tomography and low contrast vision sensitivity to test vision. The study participant will be escorted to the MRI unit to complete a non-contrast MRI of the brain. At the baseline visit, participants will be randomized. Participants assigned to the intervention diets will be given intervention specific educational materials including shopping lists, example menus and recipes, and the study supplements. Study participants randomized to the dietary guidelines for Americans diet will receive emails and/or text messages (approximately 3-6 weeks) to receive resources with websites for the Dietary Guidelines of America, and recent multiple sclerosis-related research that does not involve diet.
Study team will provide fish oil, essential fatty acids, and phosphatidylcholine to the two intervention groups only. The participant will be scheduled for a Zoom video conference meeting with the assigned registered dietitian to review the assigned study diet.
In addition, subjects will collect saliva specimens for microbiome analysis at each of the 3 site study visits (months 0, 3 and 24).
Dietary History Questionnaire III will be completed at months 0, 3, 12 and 24 and will be used to assess adherence to the assigned dietary pattern.
The online questionnaires sent to participants every 3 months will also be used to track supplement intake, medication use, and details about health & life events, MS symptoms, fatigue, quality of life, doctor's appointment, and side effects they may be experiencing.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Iowa
-
Iowa City, Iowa, Estados Unidos, 52246
- Univeristy of Iowa
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Eligibility for the run-in phase of the study:
Participants will be eligible to enroll in the fourteen-day run-in phase of the study if they meet the following inclusion and exclusion criteria:
INCLUSION CRITERIA:
- A definitive diagnosis of RRMS based on the 2017 revised McDonald Criteria.
- The ability to prepare, or availability of someone to prepare, home-cooked meals.
- Must own a computer, smartphone, or tablet device that has internet access to complete online surveys and capable of running study related applications.
- Must be willing to follow study procedures outlined and explained to them.
- Be between the ages of 18 to 70 at the time of consent.
- Must be able to walk 25 feet without support.
- Willingness to be randomized and follow any of the study diets.
- Must consent to sharing the clinical notes from their primary care and neurology providers during the study period.
EXCLUSION CRITERIA:
- Moderate or severe mental impairment.
- Use of insulin, Coumadin, weight loss medications such as orlistat that causes fat malabsorption.
- Worsening of symptoms resulting in the initiation or change of treatment including steroids (solumedrol, prednisone, etc.) or disease-modifying medications in 4 weeks prior to consent.
- Treatment for cancer by radiation or chemotherapy in 12 months prior to consent, other than skin cancer.
- Diagnosis of clinically significant heart disease, liver disease, kidney disease, or history of oxalate kidney stones.
- Diagnosis of type II diabetes that does not have approval from treating physicians to adopt any of the 3 study diets.
- Clinical diagnosis of moderate to severe psychiatric disease that makes study adherence more difficult (e.g., schizophrenia, bi-polar disease, severe depression and/or anxiety).
- An active eating disorder such as anorexia, bulimia, binge eating, or orthorexia.
- Measurement of BMI <20.
- Confirmation of pregnancy or planning to become pregnant in the next 2 years.
- History of diagnosed fat intolerance/malabsorption such as cholecystectomy or uncontrolled exocrine pancreatic insufficiency.
- Participation in another research study investigating MS treatments, diet, or exercise.
- Presence of a contraindication to completing a brain MRI or having claustrophobia which interferes with completion of MRI studies without the use of sedation.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Cuidados de suporte
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Dobro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Group 1 (Modified paleolithic elimination diet).
Modified paleolithic elimination diet. |
nutraceutical supplement
Outros nomes:
nutraceutical supplement
Outros nomes:
nutraceutical supplement
Outros nomes:
|
|
Experimental: Group 2 (TROO)
Time Restricted Olive Oil Based (TROO) Ketogenic Diet |
nutraceutical supplement
Outros nomes:
nutraceutical supplement
Outros nomes:
nutraceutical supplement
Outros nomes:
|
|
Comparador Ativo: Group 3 Control
Usual diet with Dietary Guidelines for Americans Diet information |
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Multiple Sclerosis 54 Quality of Life Mental Health (MS 54 QoL MH)
Prazo: baseline to 3 Months
|
Change in (MS 54 QoL MH) survey questions mean scores, range 0-100, higher number is better. |
baseline to 3 Months
|
|
Multiple Sclerosis 54 Quality of Life Mental Health (MS 54 QoL MH)
Prazo: baseline to 6 Months
|
Change in (MS 54 QoL MH) survey questions mean scores, range 0-100, higher number is better. |
baseline to 6 Months
|
|
Multiple Sclerosis 54 Quality of Life Mental Health (MS 54 QoL MH)
Prazo: baseline to 12 Months
|
Change in (MS 54 QoL MH) survey questions mean scores, range 0-100, higher number is better. |
baseline to 12 Months
|
|
Multiple Sclerosis 54 Quality of Life Mental Health (MS 54 QoL MH)
Prazo: baseline to 18 Months
|
Change in (MS 54 QoL MH) survey questions mean scores, range 0-100, higher number is better. |
baseline to 18 Months
|
|
Multiple Sclerosis 54 Quality of Life Mental Health (MS 54 QoL MH)
Prazo: baseline to 24 Months
|
Change in (MS 54 QoL MH) survey questions mean scores, range 0-100, higher number is better. |
baseline to 24 Months
|
|
Multiple Sclerosis 54 Quality of Life Physical Health (MS 54 QoL PH)
Prazo: baseline to 3 Months
|
Change in (MS 54 QoL PH) survey questions mean scores, range 0-100, higher number is better. |
baseline to 3 Months
|
|
Multiple Sclerosis 54 Quality of Life Physical Health (MS 54 QoL PH)
Prazo: baseline to 6 Months
|
Change in (MS 54 QoL PH) survey questions mean scores, range 0-100, higher number is better. |
baseline to 6 Months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Modified Fatigue Impact Scale (MFIS)
Prazo: baseline to 3 months
|
Change in MFIS survey questions, scores range from 0-84, lower score is better. |
baseline to 3 months
|
|
Modified Fatigue Impact Scale (MFIS)
Prazo: baseline to 6 months
|
Change in MFIS survey questions, scores range from 0-84, lower score is better. |
baseline to 6 months
|
|
Modified Fatigue Impact Scale (MFIS)
Prazo: baseline to 12 months
|
Change in MFIS survey questions, scores range from 0-84, lower score is better. |
baseline to 12 months
|
|
Modified Fatigue Impact Scale (MFIS)
Prazo: baseline to 18 months
|
Change in MFIS survey questions, scores range from 0-84, lower score is better. |
baseline to 18 months
|
|
Modified Fatigue Impact Scale (MFIS)
Prazo: baseline to 24 months
|
Change in MFIS survey questions, scores range from 0-84, lower score is better. |
baseline to 24 months
|
|
Hospital Anxiety Depression Scale (HADS)
Prazo: baseline to 3 months
|
Change in HADS survey question score, a 14 question scale ranging from 0-3 with zero being being low or no occurrence and 3 being high occurrence |
baseline to 3 months
|
|
Hospital Anxiety Depression Scale (HADS)
Prazo: baseline to 6 months
|
Change in HADS survey question score, a 14 question scale ranging from 0-3 with zero being being low or no occurrence and 3 being high occurrence |
baseline to 6 months
|
|
Hospital Anxiety Depression Scale (HADS)
Prazo: baseline to 12 months
|
Change in HADS survey question score, a 14 question scale ranging from 0-3 with zero being being low or no occurrence and 3 being high occurrence |
baseline to 12 months
|
|
Hospital Anxiety Depression Scale (HADS)
Prazo: baseline to 18 months
|
Change in HADS survey question score, a 14 question scale ranging from 0-3 with zero being being low or no occurrence and 3 being high occurrence |
baseline to 18 months
|
|
Hospital Anxiety Depression Scale (HADS)
Prazo: baseline to 24 months
|
Change in HADS survey question score, a 14 question scale ranging from 0-3 with zero being being low or no occurrence and 3 being high occurrence |
baseline to 24 months
|
|
Fatigue Severity Scale score (FSS)
Prazo: Baseline to 3 months
|
Change in FSS survey question mean scores, scores range from 1-7, lower is better. |
Baseline to 3 months
|
|
Fatigue Severity Scale score (FSS)
Prazo: Baseline to 6 months
|
Change in FSS survey question mean scores, scores range from 1-7, lower is better. |
Baseline to 6 months
|
|
Fatigue Severity Scale score (FSS)
Prazo: Baseline to 12 months
|
Change in FSS survey question mean scores, scores range from 1-7, lower is better. |
Baseline to 12 months
|
|
Fatigue Severity Scale score (FSS)
Prazo: Baseline to 18 months
|
Change in FSS survey question mean scores, scores range from 1-7, lower is better. |
Baseline to 18 months
|
|
Fatigue Severity Scale score (FSS)
Prazo: Baseline to 24 months
|
Change in FSS survey question mean scores, scores range from 1-7, lower is better. |
Baseline to 24 months
|
|
Brain volume as measured by non contrast magnetic resonance imaging (MRI)
Prazo: baseline to 24 months
|
Change in MRI grey matter brain volume, more is better |
baseline to 24 months
|
|
Brain lesions as measured by non contrast magnetic resonance imaging (MRI)
Prazo: baseline to 24 months
|
Change in inflammatory lesions numbers as measured by non contrast brain MRI, fewer is better |
baseline to 24 months
|
|
Timed 25 foot walk test
Prazo: baseline to 3 months
|
seconds required to walk 25 feet, lower is better |
baseline to 3 months
|
|
Timed 25 foot walk test
Prazo: baseline to 24 months
|
seconds required to walk 25 feet, lower is better |
baseline to 24 months
|
|
9 Hole peg board test
Prazo: baseline to 3 months
|
seconds require to move 9 pegs to various locations on a peg board, fewer seconds is better |
baseline to 3 months
|
|
9 Hole peg board test
Prazo: baseline to 24 months
|
seconds require to move 9 pegs to various locations on a peg board, fewer seconds is better |
baseline to 24 months
|
|
Low contrast visual acuity
Prazo: baseline to 3 months
|
A measure of best corrected vision, measure is log minimal angle of resolution at 2.5% contrast. Lower number is better. |
baseline to 3 months
|
|
Low contrast visual acuity
Prazo: baseline to 24 months
|
A measure of best corrected vision, measure is log minimal angle of resolution at 2.5% contrast. Lower number is better. |
baseline to 24 months
|
|
Dietary History Questionnaire IIi
Prazo: baseline to 12 months
|
Change in dietary intake measured by survey questions |
baseline to 12 months
|
|
Dietary History Questionnaire IIi
Prazo: baseline to 3 months
|
Change in dietary intake measured by survey questions |
baseline to 3 months
|
|
Critical flicker fusion
Prazo: baseline to 3 months
|
change in The herz at which a flickering light is seen as non-flickering as measured by herz |
baseline to 3 months
|
|
Critical flicker fusion
Prazo: baseline to 24 months
|
change in The herz at which a flickering light is seen as non-flickering as measured by herz |
baseline to 24 months
|
|
Ocular Coherence tomography
Prazo: baseline
|
Measure of optic nerve and retina depths using infrared light technology |
baseline
|
|
Ocular Coherence tomography
Prazo: baseline to 3 months
|
change in the Measure of optic nerve and retina depths using infrared light technology |
baseline to 3 months
|
|
Ocular Coherence tomography
Prazo: baseline to 24 months
|
change in the Measure of optic nerve and retina depths using infrared light technology |
baseline to 24 months
|
|
Neurofilament light chain
Prazo: baseline to 3 months
|
blood biomarker of neuroaxonal (brain) damage |
baseline to 3 months
|
|
Neurofilament light chain
Prazo: baseline to 24 months
|
blood biomarker of neuroaxonal (brain) damage |
baseline to 24 months
|
|
Multiple Sclerosis 54 Quality of Life Physical Health (MS 54 QoL PH)
Prazo: baseline to 12 Months
|
Change in (MS 54 QoL PH) survey questions mean scores, range 0-100, higher number is better. |
baseline to 12 Months
|
|
Multiple Sclerosis 54 Quality of Life Physical Health (MS 54 QoL PH)
Prazo: baseline to 18 Months
|
Change in (MS 54 QoL PH) survey questions mean scores, range 0-100, higher number is better. |
baseline to 18 Months
|
|
Multiple Sclerosis 54 Quality of Life Physical Health (MS 54 QoL PH)
Prazo: baseline to 24 Months
|
Change in (MS 54 QoL PH) survey questions mean scores, range 0-100, higher number is better. |
baseline to 24 Months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Terry L Wahls, MD, University of Iowa
Publicações e links úteis
Publicações Gerais
- Wahls TL, Chenard CA, Snetselaar LG. Review of Two Popular Eating Plans within the Multiple Sclerosis Community: Low Saturated Fat and Modified Paleolithic. Nutrients. 2019 Feb 7;11(2):352. doi: 10.3390/nu11020352.
- Wahls T, Scott MO, Alshare Z, Rubenstein L, Darling W, Carr L, Smith K, Chenard CA, LaRocca N, Snetselaar L. Dietary approaches to treat MS-related fatigue: comparing the modified Paleolithic (Wahls Elimination) and low saturated fat (Swank) diets on perceived fatigue in persons with relapsing-remitting multiple sclerosis: study protocol for a randomized controlled trial. Trials. 2018 Jun 4;19(1):309. doi: 10.1186/s13063-018-2680-x.
- Chenard CA, Rubenstein LM, Snetselaar LG, Wahls TL. Nutrient Composition Comparison between a Modified Paleolithic Diet for Multiple Sclerosis and the Recommended Healthy U.S.-Style Eating Pattern. Nutrients. 2019 Mar 1;11(3):537. doi: 10.3390/nu11030537.
- Titcomb TJ, Bisht B, Moore DD 3rd, Chhonker YS, Murry DJ, Snetselaar LG, Wahls TL. Eating Pattern and Nutritional Risks among People with Multiple Sclerosis Following a Modified Paleolithic Diet. Nutrients. 2020 Jun 20;12(6):1844. doi: 10.3390/nu12061844.
- Lee JE, Bisht B, Hall MJ, Rubenstein LM, Louison R, Klein DT, Wahls TL. A Multimodal, Nonpharmacologic Intervention Improves Mood and Cognitive Function in People with Multiple Sclerosis. J Am Coll Nutr. 2017 Mar-Apr;36(3):150-168. doi: 10.1080/07315724.2016.1255160. Epub 2017 Apr 10.
- Lee JE, Titcomb TJ, Bisht B, Rubenstein LM, Louison R, Wahls TL. A Modified MCT-Based Ketogenic Diet Increases Plasma beta-Hydroxybutyrate but Has Less Effect on Fatigue and Quality of Life in People with Multiple Sclerosis Compared to a Modified Paleolithic Diet: A Waitlist-Controlled, Randomized Pilot Study. J Am Coll Nutr. 2021 Jan;40(1):13-25. doi: 10.1080/07315724.2020.1734988. Epub 2020 Mar 26.
- Chenard CA, Rubenstein LM, Snetselaar LG, Wahls TL. Nutrient Composition Comparison between the Low Saturated Fat Swank Diet for Multiple Sclerosis and Healthy U.S.-Style Eating Pattern. Nutrients. 2019 Mar 13;11(3):616. doi: 10.3390/nu11030616.
- Irish AK, Erickson CM, Wahls TL, Snetselaar LG, Darling WG. Randomized control trial evaluation of a modified Paleolithic dietary intervention in the treatment of relapsing-remitting multiple sclerosis: a pilot study. Degener Neurol Neuromuscul Dis. 2017 Jan 4;7:1-18. doi: 10.2147/DNND.S116949. eCollection 2017.
- Bisht B, Darling WG, Grossmann RE, Shivapour ET, Lutgendorf SK, Snetselaar LG, Hall MJ, Zimmerman MB, Wahls TL. A multimodal intervention for patients with secondary progressive multiple sclerosis: feasibility and effect on fatigue. J Altern Complement Med. 2014 May;20(5):347-55. doi: 10.1089/acm.2013.0188. Epub 2014 Jan 29.
- Shemirani F, Klein AM, Groux AR, Kilpatrick R, Brooks L, Ehlinger MA, Darling WG, Magnotta VA, Gill CM, Hoth KF, Mangalam A, Eyck PT, Martinez AS, Hook J, Titcomb TJ, Snetselaar LG, Wahls TL. Efficacy of Diet on Quality of life in Multiple Sclerosis (EDQ-MS): a study protocol for a randomized controlled clinical trial. Trials. 2025 Oct 27;26(1):437. doi: 10.1186/s13063-025-09157-2.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças do Sistema Nervoso
- Doenças autoimunes
- Doenças do sistema imunológico
- Doenças Autoimunes Desmielinizantes, SNC
- Doenças Autoimunes do Sistema Nervoso
- Doenças Desmielinizantes
- Condições Patológicas, Sinais e Sintomas
- Sinais e sintomas
- Esclerose múltipla
- Fadiga
- Esclerose Múltipla Recorrente-Remitente
- Terapêutica
- Ácidos graxos
- Lipídios
- Dieta, comida e nutrição
- Fenômenos fisiológicos
- Fenômenos fisiológicos nutricionais
- Economia de saúde e organizações
- Dieta terapia
- Terapia nutricional
- Dieta
- Eicosanóides
- Ácidos graxos, insaturados
- Dieta, restrito a carboidratos
- Óleos
- Gorduras alimentares
- Gorduras
- Ácidos graxos, ômega-3
- Gorduras alimentares, insaturadas
- Óleos de peixe
- Lipídios da membrana
- Glicerofosfolipídios
- Ácidos fosfatídicos
- Glicerofosfatos
- Fosfolipídios
- Política de Saúde
- Políticas públicas
- Políticas de controle social
- Política
- Dieta, cetogênica
- Ácido eicosapentaenóico
- Ácidos docosahexaenóicos
- Fosfatidilcolinas
- Política de nutrição
Outros números de identificação do estudo
- 202104639
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Data that has been published will be shared if requested by a scientist conducting a PROSPERO registered meta-analyses who has signed a data use agreement with the University of Iowa Department of Sponsored Programs.
Prazo de Compartilhamento de IPD
One year after the specific data has been published.
Critérios de acesso de compartilhamento IPD
A scientist who has a PROSPERO registered meta-analysis whose meta-analysis protocol has been published. The scientist must contact the PI using their academic email, provide the published PROSPERO registered meta-analysis protocol manuscript, specify which data is being requested. Upon review of the submitted documents, the PI will initiated an outcoing material data use agreement with the Division of Sponsored Programs at the University of Iowa outlining the terms of use. After signing the approved contract, the data will be released to the requesting scientist.
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- CIF
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .